- Home
- SDHC vs LQDA Comparison
SDHC vs LQDA Comparison
Compare SDHC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- LQDA
- Stock Information
- Founded
- SDHC 2008
- LQDA 2004
- Country
- SDHC United States
- LQDA United States
- Employees
- SDHC N/A
- LQDA N/A
- Industry
- SDHC
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- LQDA Health Care
- Exchange
- SDHC Nasdaq
- LQDA Nasdaq
- Market Cap
- SDHC 1.2B
- LQDA 1.3B
- IPO Year
- SDHC 2024
- LQDA 2018
- Fundamental
- Price
- SDHC $19.51
- LQDA $14.75
- Analyst Decision
- SDHC Hold
- LQDA Strong Buy
- Analyst Count
- SDHC 4
- LQDA 7
- Target Price
- SDHC $30.50
- LQDA $28.33
- AVG Volume (30 Days)
- SDHC 89.5K
- LQDA 909.5K
- Earning Date
- SDHC 03-12-2025
- LQDA 03-19-2025
- Dividend Yield
- SDHC N/A
- LQDA N/A
- EPS Growth
- SDHC N/A
- LQDA N/A
- EPS
- SDHC 1.81
- LQDA N/A
- Revenue
- SDHC $975,463,000.00
- LQDA $13,996,000.00
- Revenue This Year
- SDHC $9.69
- LQDA $256.78
- Revenue Next Year
- SDHC $13.27
- LQDA $222.00
- P/E Ratio
- SDHC $10.71
- LQDA N/A
- Revenue Growth
- SDHC 27.57
- LQDA N/A
- 52 Week Low
- SDHC $18.53
- LQDA $8.26
- 52 Week High
- SDHC $39.50
- LQDA $16.81
- Technical
- Relative Strength Index (RSI)
- SDHC 40.11
- LQDA 47.33
- Support Level
- SDHC $18.95
- LQDA $14.84
- Resistance Level
- SDHC $20.91
- LQDA $15.59
- Average True Range (ATR)
- SDHC 1.26
- LQDA 0.65
- MACD
- SDHC 0.05
- LQDA -0.00
- Stochastic Oscillator
- SDHC 24.81
- LQDA 45.59
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.